Structure analysis of the receptor binding of 2019-nCoV

Abstract

2019-nCoV is a newly identified coronavirus with high similarity to SARS-CoV. We performed a structural analysis of the receptor binding domain (RBD) of spike glycoprotein responsible for entry of coronaviruses into host cells. The RBDs from the two viruses share 72% identity in amino acid sequences, and molecular simulation reveals highly similar ternary structures. However, 2019-nCoV has a distinct loop with flexible glycyl residues replacing rigid prolyl residues in SARS-CoV. Molecular modeling revealed that 2019-nCoV RBD has a stronger interaction with angiotensin converting enzyme 2 (ACE2). A unique phenylalanine F486 in the flexible loop likely plays a major role because its penetration into a deep hydrophobic pocket in ACE2. ACE2 is widely expressed with conserved primary structures throughout the animal kingdom from fish, amphibians, reptiles, birds, to mammals. Structural analysis suggests that ACE2 from these animals can potentially bind RBD of 2019-nCoV, making them all possible natural hosts for the virus. 2019-nCoV is thought to be transmitted through respiratory droplets. However, since ACE2 is predominantly expressed in intestines, testis, and kidney, fecal-oral and other routes of transmission are also possible. Finally, antibodies and small molecular inhibitors that can block the interaction of ACE2 with RBD should be developed to combat the virus.

Cited by papers we hold 14

• COVID-19: Characteristics and Therapeutics · 2021
  No notice
• Coronavirus disease and male fertility: a systematic review · 2021
  Not checked
• Major Insights in Dynamics of Host Response to SARS-CoV-2: Impacts and Challenges · 2021
  Not checked
• Impact of RAAS Inhibitors on Clinical Outcome and Mortality in Patients With STEMI During the COVID-19 Era: A Multicenter Observational Study · 2021
  Not checked
• Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies · 2021
  No notice
• Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2 · 2021
  No notice
• Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids · 2020
  No notice
• Repurposing existing drugs for COVID-19: an endocrinology perspective · 2020
  Not checked
• Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis · 2020
  No notice
• Biological sex impacts COVID-19 outcomes · 2020
  No notice
• Immune Response, Inflammation, and the Clinical Spectrum of COVID-19 · 2020
  No notice
• An Overview of SARS-CoV-2 and Animal Infection · 2020
  No notice
• COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment · 2020
  No notice
• Inflammation Triggered by SARS-CoV-2 and ACE2 Augment Drives Multiple Organ Failure of Severe COVID-19: Molecular Mechanisms and Implications · 2020
  No notice

Questions about this paper

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.